Impact of COVID-19 pandemic on Tuberculosis and HIV services in Ghana: An interrupted time series analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
10
2022
accepted:
06
09
2023
medline:
22
9
2023
pubmed:
20
9
2023
entrez:
20
9
2023
Statut:
epublish
Résumé
The Coronavirus disease 2019 (COVID-19) burden, coupled with unprecedented control measures including physical distancing, travel bans, and lockdowns of cities, implemented to stop the spread of the virus, have undoubtedly far-reaching aftereffects on other diseases. In low and middle-income countries (LMICs), a particular worry is the potential impact on Human Immunodeficiency Virus (HIV) and Tuberculosis (TB), as a consequence of possible disruption to health services and limiting access to needed life-saving health care. In Ghana, there is a paucity of information regarding the impact of COVID-19 on disease control, particularly TB and HIV control. This study sought to contribute to bridging this knowledge gap. The study involved the analysis of secondary data obtained from the District Health Information Management System-2 (DHIMS-2) database of Ghana Health Service, from 2016 to 2020. Data were analysed using an interrupted time-series regression approach to estimate the impact of COVID-19 on TB case notification, HIV testing, and Antiretroviral Therapy (ART) initiations, using March 2020 as the event period. The study showed that during the COVID-19 pandemic period, there was an abrupt decline of 20.5% (955CI: 16.0%, 24.5%) in TB case notifications in April and 32.7% (95%CI: 28.8%, 39.1%) in May 2020, with a median monthly decline of 21.4% from April-December 2020. A cumulative loss of 2,128 (20%; 95%CI: 13.3%, 26.7%) TB cases was observed nationwide as of December 2020. There was also a 40.3% decrease in people presenting for HIV tests in the first month of COVID-19 (April 2020) and a cumulative loss of 262620 (26.5%) HIV tests as of December 2020 attributable to the COVID-19 pandemic. ART initiations increased by 39.2% in the first month and thereafter decreased by an average of 10% per month from May to September 2020. Cumulatively, 443 (1.9%) more of the people living with HIV initiated ART during the pandemic period, however, this was not statistically significant. This study demonstrated that the COVID-19 pandemic negatively impacted TB case notifications and HIV testing and counselling services, However, ART initiation was generally not impacted during the first year of the pandemic. Proactive approaches aimed at actively finding the thousands of individuals with TB who were missed in 2020 and increasing HIV testing and counselling and subsequent treatment initiations should be prioritised.
Identifiants
pubmed: 37729176
doi: 10.1371/journal.pone.0291808
pii: PONE-D-22-29420
pmc: PMC10511085
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0291808Informations de copyright
Copyright: © 2023 Osei et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur J Dev Res. 2020;32(5):1353-1378
pubmed: 33144762
Emerg Infect Dis. 2021 Jul;27(7):1831-1839
pubmed: 34152962
AIDS Behav. 2020 Nov;24(11):3010-3013
pubmed: 32488552
J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):446-53
pubmed: 16010168
EClinicalMedicine. 2020 Oct 24;28:100603
pubmed: 33134905
BMC Med. 2022 Nov 14;20(1):432
pubmed: 36372899
WHO South East Asia J Public Health. 2020 Sep;9(2):95-99
pubmed: 32978339
Lancet Glob Health. 2020 Sep;8(9):e1132-e1141
pubmed: 32673577
Ann Clin Microbiol Antimicrob. 2020 May 23;19(1):21
pubmed: 32446305
PLoS Med. 2022 Aug 30;19(8):e1004070
pubmed: 36040910
BMC Infect Dis. 2021 Aug 7;21(1):768
pubmed: 34364383
Emerg Infect Dis. 2020 Oct;26(10):2506-2508
pubmed: 32672531
Int J Tuberc Lung Dis. 2020 Sep 1;24(9):981-982
pubmed: 33156771
Trop Med Infect Dis. 2021 May 31;6(2):
pubmed: 34072803
Lancet. 2003 Jul 5;362(9377):22-9
pubmed: 12853195
Ghana Med J. 2020 Dec;54(4 Suppl):3-4
pubmed: 33976435
BMC Health Serv Res. 2021 Dec 2;21(1):1295
pubmed: 34856995
J Sex Med. 2020 Jul;17(7):1225-1228
pubmed: 32418751
Trop Med Infect Dis. 2021 May 10;6(2):
pubmed: 34068615
Int J Tuberc Lung Dis. 2020 Nov 1;24(11):1220-1222
pubmed: 33172534
Trop Med Infect Dis. 2020 Jul 24;5(3):
pubmed: 32722014
Int J Epidemiol. 2017 Feb 1;46(1):348-355
pubmed: 27283160
Gates Open Res. 2020 Jul 29;4:117
pubmed: 32954217
Ghana Med J. 2020 Dec;54(4 Suppl):1-2
pubmed: 33976434
AIDS. 2005 Mar 25;19(5):513-20
pubmed: 15764857
AIDS Behav. 2020 Nov;24(11):3006-3009
pubmed: 32451939
Lancet Reg Health West Pac. 2021 Mar 24;9:100122
pubmed: 34327438
Lancet HIV. 2021 Mar;8(3):e158-e165
pubmed: 33549166
BMJ Glob Health. 2021 Aug;6(8):
pubmed: 34281914
Lancet HIV. 2020 May;7(5):e308-e309
pubmed: 32272084
BMC Health Serv Res. 2020 Jun 6;20(1):514
pubmed: 32505209
Int J Tuberc Lung Dis. 2020 Oct 1;24(10):1122-1124
pubmed: 33126952
Pan Afr Med J. 2021 Mar 08;38:243
pubmed: 34104291
Anim Front. 2021 Feb 05;11(1):43-46
pubmed: 33575100
Indian J Tuberc. 2021 Jan;68(1):142-145
pubmed: 33641836
PLoS Negl Trop Dis. 2019 Feb 27;13(2):e0007185
pubmed: 30811388
Lancet HIV. 2020 May;7(5):e319-e320
pubmed: 32277870
BMJ Open. 2020 Oct 5;10(10):e043763
pubmed: 33020109
HIV Med. 2009 Aug;10(7):432-8
pubmed: 19459996
BMJ Glob Health. 2022 May;7(5):
pubmed: 35501068
AIDS Care. 2007 Apr;19(4):523-31
pubmed: 17453593
Lancet Glob Health. 2022 Dec;10(12):e1774-e1781
pubmed: 36400083
Trop Med Infect Dis. 2021 May 19;6(2):
pubmed: 34069332
PLoS One. 2021 Feb 2;16(2):e0244936
pubmed: 33529206
Lancet HIV. 2020 Sep;7(9):e629-e640
pubmed: 32771089